SIA
ABBV icon

Soltis Investment Advisors’s AbbVie ABBV Stock Holding History

Soltis Investment Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.03M Buy
35,875
+2,206
+7% +$475K 0.5% 50
2026
Q1 		$7.32M Sell
33,669
-408
-1% -$90.5K 0.46% 54
2025
Q4 		$7.79M Buy
34,077
+12,096
+55% +$2.76M 0.51% 44
2025
Q3 		$5.09M Sell
21,981
-277
-1% -$56.4K 0.35% 69
2025
Q2 		$4.13M Buy
22,258
+1,910
+9% +$355K 0.32% 79
2025
Q1 		$4.26M Sell
20,348
-288
-1% -$56K 0.38% 73
2024
Q4 		$3.67M Sell
20,636
-26,822
-57% -$4.93M 0.34% 83
2024
Q3 		$9.37M Sell
47,458
-765
-2% -$143K 0.92% 19
2024
Q2 		$8.27M Buy
48,223
+28,649
+146% +$4.75M 0.88% 21
2024
Q1 		$3.56M Buy
19,574
+1
+0% +$172 0.4% 84
2023
Q4 		$3.03M Sell
19,573
-757
-4% -$110K 0.34% 88
2023
Q3 		$3.03M Buy
20,330
+540
+3% +$79.3K 0.39% 81
2023
Q2 		$2.67M Buy
19,790
+233
+1% +$34.2K 0.31% 88
2023
Q1 		$3.12M Buy
19,557
+1,383
+8% +$211K 0.4% 73
2022
Q4 		$2.94M Buy
18,174
+382
+2% +$58.6K 0.39% 73
2022
Q3 		$2.39M Buy
17,792
+171
+1% +$24.5K 0.36% 77
2022
Q2 		$2.7M Buy
17,621
+909
+5% +$139K 0.39% 72
2022
Q1 		$2.71M Buy
16,712
+181
+1% +$26.3K 0.38% 66
2021
Q4 		$2.24M Sell
16,531
-8
-0% -$945 0.32% 70
2021
Q3 		$1.78M Buy
16,539
+162
+1% +$18.5K 0.28% 78
2021
Q2 		$1.84M Sell
16,377
-6
-0% -$676 0.29% 71
2021
Q1 		$1.77M Buy
16,383
+50
+0.3% +$5.35K 0.32% 62
2020
Q4 		$1.75M Sell
16,333
-122
-0.7% -$11.7K 0.32% 54
2020
Q3 		$1.44M Buy
16,455
+14,232
+640% +$1.34M 0.34% 58
2020
Q2 		$218K Buy
+2,223
New +$196K 0.06% 170

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Soltis Investment Advisors's ABBV Position: Q2 2026 in Review

Soltis Investment Advisors increased its AbbVie (ABBV) stake by 6.6% in Q2 2026, buying an estimated $475K and bringing the position to 35,875 shares worth $9.03M. The position accounts for 0.5% of the portfolio, ranked #50.

Soltis Investment Advisors first reported a position in ABBV in Q2 2020 and has held it in 25 quarters since. The position peaked at $9.37M in Q3 2024. 4,225 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Soltis Investment Advisors held 35,875 shares of AbbVie worth $9.03M as of Q2 2026.
  • Soltis Investment Advisors bought 2,206 AbbVie shares in Q2 2026, an estimated $475K.
  • AbbVie made up 0.5% of Soltis Investment Advisors's portfolio in Q2 2026, its #50 holding.
  • Soltis Investment Advisors first reported a position in AbbVie in Q2 2020 and has held it in 25 quarters since.
  • Soltis Investment Advisors's AbbVie position peaked at $9.37M in Q3 2024.
  • 4,225 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Soltis Investment Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.